The Department of Health decision was based on Health Protection Agency surveillance data showing an increase in flu activity.
Further information regarding at-risk groups and patients who are eligible for treatment at NHS expense with either Tamiflu (oseltamivir) or Relenza (zanamivir) can be found in Part XVIIIB of the Drug Tarrif.
GPs will be required to endorse prescriptions for the two influenza drugs with ‘SLS’.
Viroflu now available
Further information: Green Book – Chapter 19: Influenza